BidaskClub lowered shares of Sientra (NASDAQ:SIEN) from a hold rating to a sell rating in a research report released on Tuesday, November 13th.
SIEN has been the subject of several other research reports. Zacks Investment Research downgraded Sientra from a hold rating to a sell rating in a research note on Thursday, October 4th. Canaccord Genuity raised their target price on Sientra from $19.00 to $25.00 and gave the stock a buy rating in a research note on Wednesday, August 8th. Stephens restated a buy rating and issued a $30.00 target price on shares of Sientra in a research note on Thursday, August 9th. Stifel Nicolaus raised their target price on Sientra from $21.00 to $25.00 and gave the stock a buy rating in a research note on Wednesday, August 8th. Finally, Dougherty & Co began coverage on Sientra in a research note on Thursday, August 30th. They issued a buy rating and a $31.00 target price for the company. One analyst has rated the stock with a sell rating, one has assigned a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of Buy and an average target price of $22.50.
Shares of SIEN stock traded up $0.20 on Tuesday, hitting $18.00. 389,200 shares of the stock were exchanged, compared to its average volume of 414,320. The company has a debt-to-equity ratio of 0.36, a quick ratio of 2.34 and a current ratio of 2.77. The company has a market capitalization of $509.07 million, a price-to-earnings ratio of -6.43 and a beta of -0.42. Sientra has a one year low of $8.79 and a one year high of $26.79.
Sientra (NASDAQ:SIEN) last posted its quarterly earnings results on Tuesday, November 6th. The medical instruments supplier reported ($0.72) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.05). The firm had revenue of $16.90 million for the quarter, compared to the consensus estimate of $16.66 million. Sientra had a negative return on equity of 132.84% and a negative net margin of 126.03%. The firm’s revenue was up 72.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.74) EPS. Equities analysts predict that Sientra will post -3.05 EPS for the current year.
In other Sientra news, Director Timothy Haines sold 89,651 shares of the firm’s stock in a transaction dated Tuesday, November 6th. The stock was sold at an average price of $21.56, for a total value of $1,932,875.56. Following the sale, the director now owns 37,662 shares of the company’s stock, valued at approximately $811,992.72. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 31.00% of the company’s stock.
Large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its holdings in shares of Sientra by 1.4% during the 3rd quarter. Vanguard Group Inc. now owns 1,017,312 shares of the medical instruments supplier’s stock valued at $24,293,000 after buying an additional 14,422 shares in the last quarter. Teachers Advisors LLC raised its holdings in shares of Sientra by 29.1% during the 3rd quarter. Teachers Advisors LLC now owns 47,673 shares of the medical instruments supplier’s stock valued at $1,138,000 after buying an additional 10,732 shares in the last quarter. AQR Capital Management LLC raised its holdings in shares of Sientra by 41.5% during the 3rd quarter. AQR Capital Management LLC now owns 19,345 shares of the medical instruments supplier’s stock valued at $462,000 after buying an additional 5,675 shares in the last quarter. MetLife Investment Advisors LLC raised its holdings in shares of Sientra by 55.2% during the 3rd quarter. MetLife Investment Advisors LLC now owns 17,996 shares of the medical instruments supplier’s stock valued at $430,000 after buying an additional 6,397 shares in the last quarter. Finally, Point72 Asset Management L.P. purchased a new position in shares of Sientra during the 3rd quarter valued at about $3,767,000. 87.01% of the stock is currently owned by hedge funds and other institutional investors.
Sientra Company Profile
Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.
Featured Story: What are Closed-End Mutual Funds?
Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.